Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LM-24C5 combined with other antitumor therapies in CEACAM5-positive advanced solid tumors
CTR20254377Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LM-24C5 in Nonhematologic neoplasms, sponsored by LaNova Medicines. Started Dec 2025; status: active.
02
Drugs
LM-24C5
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254377.